Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02242981 · ClinicalTrials.gov registry record · Phase 1
A Study of How the Body Breaks Down and Eliminates LY2623091
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02242981 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 6 participants.
The verdict
NCT02242981, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This type of study is called a radiolabeled study. For this study, LY2623091 (study drug) has been specially prepared to contain radiolabeled carbon \[\^14C\]. \[\^14C\] is a naturally occurring radioactive form of the element, carbon. This study will increase understanding about how the drug appears in the blood, urine, and stool after it is administered to healthy participants. Information about any side effects that may occur will also be collected. This study will last up to 22 days for each participant, not including screening. Screening is required within 28 days prior to enrollment
Interventions
- DRUG LY2623091
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-09 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02242981
The ClinicalTrials.gov registry entry for NCT02242981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2623091 is the first listed.
NCT02242981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02242981 about?
NCT02242981 is a clinical study titled "A Study of How the Body Breaks Down and Eliminates LY2623091". This type of study is called a radiolabeled study. For this study, LY2623091 (study drug) has been specially prepared to contain radiolabeled carbon \[\^14C\]. \[\^14C\] is a naturally occurring radioactive form of the element, carbon. This study will increase understanding about how the drug appear...
What is the current status of trial NCT02242981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-09. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02242981?
The interventions under investigation include: LY2623091 (DRUG).
Who is sponsoring clinical trial NCT02242981?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.